Literature DB >> 8293279

A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.

M P Heyes1, K Saito, E O Major, S Milstien, S P Markey, J H Vickers.   

Abstract

Quinolinic acid (QUIN), kynurenic acid (KYNA) and L-kynurenine (L-KYN) are neuroactive kynurenine pathway metabolites that accumulate in inflammatory neurological diseases. These increases were attributed to the induction of indoleamine-2,3-dioxygenase (IDO), the enzyme that converts L-tryptophan into L-KYN. Direct conversion of L-tryptophan into QUIN by brain tissue occurs in conditions of CNS inflammation, but not by normal brain tissue. To investigate whether increased activity of enzymes distal to IDO may determine L-KYN conversion to QUIN, rhesus macaques were inoculated with poliovirus directly into the spinal cord, as a model of focal inflammatory neurological disease (FASEB J. 6, 2977-2989, 1992). Induction of spinal cord IDO (35.9-fold) accompanied smaller, but proportional increases in kynurenine-3-hydroxylase (2.4-fold) and kynureninase (2.3-fold) activities, which were correlated to CSF and tissue QUIN levels, as well as to measures of inflammatory lesions. 3-Hydroxyanthranilate-3,4-dioxygenase activity was unchanged. Cerebrospinal fluid KYNA levels increased in proportion to both IDO activity and L-KYN accumulation, though kynurenine aminotransferase activity was unaffected. Cerebrospinal fluid neopterin, a marker of macrophage and immune activation, accumulated in proportion to the responsive enzymes and metabolites. The cell types involved in producing QUIN were investigated in vitro. Human foetal brain cultures consisting of astrocytes and neurons converted large quantities of [13C6]L-tryptophan into L-KYN when stimulated by gamma-interferon, but very little [13C6]QUIN was formed unless macrophages (THP-1 cells) were first added to the cultures (to model a key component of brain inflammation). [13C6]L-Tryptophan was converted into [13C6]QUIN by either gamma-interferon stimulated macrophages, or following intracisternal administration into poliovirus-infected macaques. Inhibitors of the kynurenine pathway, 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilic acid, attenuated [13C6]QUIN formation by macrophages, and when co-infused with [13C6]L-tryptophan into poliovirus-infected macaques. These results suggest roles for increased activities of IDO, kynurenine-3-hydroxylase and kynureninase in accelerating the synthesis of QUIN, L-KYN and KYNA in conditions of brain inflammation. Macrophage infiltrates, and perhaps microglia, are important sources of QUIN, whereas constitutive brain cells and macrophages are sources of L-KYN. Drugs that inhibit kynurenine pathway enzymes attenuate QUIN formation in the CNS, and provide tools to examine the consequences of reduced QUIN accumulation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8293279     DOI: 10.1093/brain/116.6.1425

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  41 in total

1.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Authors:  Bianca D Santomasso; Jae H Park; Darin Salloum; Isabelle Riviere; Jessica Flynn; Elena Mead; Elizabeth Halton; Xiuyan Wang; Brigitte Senechal; Terence Purdon; Justin R Cross; Hui Liu; Behroze Vachha; Xi Chen; Lisa M DeAngelis; Daniel Li; Yvette Bernal; Mithat Gonen; Hans-Guido Wendel; Michel Sadelain; Renier J Brentjens
Journal:  Cancer Discov       Date:  2018-06-07       Impact factor: 39.397

Review 3.  Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.

Authors:  Gislaine Z Réus; Karen Jansen; Stephanie Titus; André F Carvalho; Vilma Gabbay; João Quevedo
Journal:  J Psychiatr Res       Date:  2015-05-19       Impact factor: 4.791

4.  Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.

Authors:  Jennifer C Felger; Li Li; Paul J Marvar; Bobbi J Woolwine; David G Harrison; Charles L Raison; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2012-10-13       Impact factor: 7.217

Review 5.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

6.  Altered tryptophan metabolism in mice with herpes simplex virus encephalitis: increases in spinal cord quinolinic acid.

Authors:  J F Reinhard
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

7.  High resolution crystal structures of human kynurenine aminotransferase-I bound to PLP cofactor, and in complex with aminooxyacetate.

Authors:  Naveed A Nadvi; Noeris K Salam; Joohong Park; Fady N Akladios; Vimal Kapoor; Charles A Collyer; Mark D Gorrell; William Bret Church
Journal:  Protein Sci       Date:  2017-03-06       Impact factor: 6.725

8.  Attenuation of antigenic immunogenicity by kynurenine, a novel suppressive adjuvant.

Authors:  Zhiqing Duan; Yunqing Duan; Huangui Lei; Ningzhu Hu; Jiandong Shi; Dong Shen; Xi Wang; Yunzhang Hu
Journal:  Hum Vaccin Immunother       Date:  2014-02-28       Impact factor: 3.452

9.  Influence of miR-30b regulating humoral immune response by genetic difference.

Authors:  Zhi-Qing Duan; Jian-Dong Shi; Mei-Ni Wu; Ning-Zhu Hu; Yun-Zhang Hu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

10.  CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.

Authors:  C L Raison; R Dantzer; K W Kelley; M A Lawson; B J Woolwine; G Vogt; J R Spivey; K Saito; A H Miller
Journal:  Mol Psychiatry       Date:  2009-11-17       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.